Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...
Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...
U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...
Regeneron also said it was discontinuing a phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1 being studied as a treatment for cat allergy, due to futility. Image Phil Taylor ...
Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...
Hosted on MSN16d
Regeneron to Report Q3 Earnings: What's in the Offing?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
Shares of Regeneron Pharmaceuticals Inc. REGN inched 0.07% higher to $829.43 Tuesday, on what proved to be an all-around ...
U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback